December 2010 Reports findings from a survey that revealed that although substance abuse is prevalent in jails and prisons, many correctional facilities do not offer detoxification services or therapies to aid in maintaining abstinence.
December 2008 Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.
March 2014 Microneedles are an innovative technique for delivering medications through the skin, a route that could particularly benefit patients receiving naltrexone therapy for opioid and alcohol dependence. Researchers have found a way to use the transdermal technique to deliver a single treatment of naltrexone that lasts for 7 days.
November 2013 More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
February 2015 A significant portion of individuals who are addicted to opioid painkillers may initiate and maintain abstinence with a brief but intensive outpatient detoxification treatment followed by opioid antagonist therapy using naltrexone.
February 2015 Trial participants who were addicted to opioid painkillers and did not inject drugs stayed in treatment longer and achieved better outcomes than those who were addicted to heroin or injected drugs.